Merz Aesthetics Reveals Global Data on the Connection Between Confidence, Self-Affirmation and Aesthetic Treatments
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, today announced the findings of its inaugural global study, Pillars of Confidence: Global Insights on Aesthetics and Self-Affirmation. The study explored the role confidence plays in daily life and overall well-being, as well as the connection between our internal selves and outward expression.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250129954824/en/
Graphic: Merz Aesthetics
As part of its Confidence to Be platform, Merz Aesthetics surveyed 15,000 adults from around the world who have had an aesthetic treatment in the past or are open to having one in the near future. The Pillars of Confidence study revealed that a global majority of study participants have a strong sense of self-confidence, with 72% agreeing with the statement, “I am confident in who I am.”
The findings of the Pillars of Confidence study also link external appearance to internal self-concept. When it comes to aesthetic treatments specifically, 73% of respondents reported saying they feel “empowered” after having an aesthetic treatment, 69% seek aesthetic treatments to reflect how they feel inside and 72% said that aesthetic treatments impact how they view themselves.
Conducted in partnership with Ipsos*, one of the largest market research and polling companies globally, the Pillars of Confidence study engaged 15,000 adults aged 21 to 75** from 15 countries. Participating regions and countries included:
- Asia-Pacific: China, South Korea, Thailand
- Europe, the Middle East & Africa: France, Germany, Italy, Spain, the United Kingdom and the United Arab Emirates
- Latin America: Brazil, Colombia, Costa Rica, Mexico
- North America: United States, Canada
“Since becoming a standalone global business nearly five years ago, Merz Aesthetics has been committed to our purpose of fueling confidence by helping people look better, feel better and live better. We believe in the importance of feeling confident and what makes you feel like the best version of yourself—however you define it,” said Bob Rhatigan, CEO, Merz Aesthetics. “Our Pillars of Confidence research shows what we anecdotally knew to be true—that aesthetic treatments appear to do more than just enhance our appearance; they can help people feel empowered and support their self-confidence journey.”
“The Pillars of Confidence data shows how aesthetic treatments enable patients to take an active role in aligning their self-perception with their outward appearance,” said Dr. Shannon Humphrey, cosmetic dermatologist, medical director at Humphrey & Beleznay Cosmetic Dermatology and clinical associate professor at the University of British Columbia. “As a physician, I see this impact every day. These insights can help us better understand and support our patients as they work toward personal empowerment, which ultimately enhances the care we provide.”
Whether it’s the things we say, the people we surround ourselves with, or our choices around aesthetic treatments, Merz Aesthetics believes that every person's journey to look, feel and live their best is unique. With a purpose to fuel confidence worldwide, Merz Aesthetics hopes that the data-backed insights of the Pillars of Confidence study will inspire meaningful conversations that enable even more people to celebrate being their authentic selves, both inside and out.
For more information on the Pillars of Confidence study and to download a full report of the findings, please visit www.merzaesthetics.com/confidence.
*Merz Aesthetics. (2025). Pillars of Confidence: Global Insights on Aesthetics and Self-Affirmation. Supported by research partner Ipsos.
**Age range in Asia-Pacific region was 21 to 65.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
© 2025 Merz North America, Inc. All rights reserved. Merz, Merz Aesthetics and the Merz Aesthetics Confidence To Be Logo are trademarks and/or registered trademarks of Merz Pharma GmbH & Co. KGaA in the U.S. and/or certain other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129954824/en/
Contacts
Media Contact
Merz Aesthetics
Global Corporate Communications
6501 Six Forks Road, Raleigh NC 27615
919-302-3296
media@merz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Unveils New Post-Hoc Analyses of LIBERTY Studies at the 20 th ECCO Congress Further Evaluating the Efficacy and Safety of Subcutaneous (SC) Infliximab20.2.2025 18:45:00 EET | Press release
Celltrion announced new post-hoc analyses of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), at the 20th European Crohn’s and Colitis Organisation (ECCO) Congress showcasing the treatment’s effectiveness across a range of key clinical outcomes in inflammatory bowel disease (IBD). The analyses highlight Celltrion’s ongoing efforts to evaluate the efficacy and safety of subcutaneous (SC) infliximab (CT-P13 SC) in achieving endoscopic-histologic remission in ulcerative colitis (UC), clinical and endoscopic improvement across all disease locations in Crohn’s disease (CD), and supporting early clinical recapture after dose escalation following loss of response in CD and UC, and long-term drug persistence regardless of ADA in CD patients.3,4,5,6 LIBERTY-UC Phase III Post-Hoc Analysis (LIBERTY-UC Endo-Histological Outcome) A post-hoc analysis of the Phase 3 LIBERTY-UC study showed that maintenance therapy with SC infliximab resulted in significantly greater improvements in endoscopic
NTT DATA Launches Smart AI Agent ™ to Accelerate Generative AI Adoption and Drive $2 Billion in Revenue by 202720.2.2025 17:33:00 EET | Press release
NTT DATA, a global digital business and IT services leader, today announced the international launch of its next-generation Smart AI Agent™. This advanced AI tool is a cornerstone of the company’s strategy to accelerate the adoption of Generative AI, with an estimated $2 billion in revenue that we aim to achieve from Smart AI Agent™-related business by 2027. The Smart AI Agent™ autonomously extracts, organizes, and executes tasks in response to user instructions, complementing existing workforces and streamlining time-consuming processes. By enhancing efficiency across industries, the Smart AI Agent™ enables businesses to rapidly evaluate and deploy Generative AI applications, optimizing workflows and driving greater productivity. Yutaka Sasaki, President and CEO, NTT DATA, said: “The launch of our Smart AI Agent™ is a direct response to the growing demand for tools that unlock the full potential of Generative AI. At NTT DATA, we’re committed to pioneering innovation that drives enterp
New global guideline published on managing fungal infections caused by Candida20.2.2025 17:15:00 EET | Press release
A new global guideline for the diagnosis and treatment of Candidainfections was recently published in Lancet Infectious Diseases1. This guideline sets out new standards for managing fungal infections, which affect millions of people worldwide every year. The global guideline was developed by a team of more than 100 experts spanning 35 countries and led by Professor Dr. Oliver A. Cornely and Dr. Rosanne Sprute from University Hospital Cologne. One year following the European Medical Association (EMA)2 approval, rezafungin ▼3 has been included in the guideline, along with other echinocandins, as a strongly recommended first line therapy option for the treatment of candidaemia. Echinocandins, including rezafungin, are preferred for all forms of invasive candidiasis, excluding CNS and ocular infections, due to their broad antifungal activity and favourable safety profile. The new guideline, which took four years to develop, contains recommendations for clinicians on the prevention, diagnos
SiMa.ai and HTEC Strengthen Strategic Partnership to Advance Premium ML System-on-Chip Solutions20.2.2025 17:08:00 EET | Press release
HTEC, a global digital engineering services firm, is pleased to announce a partnership extension with SiMa.ai, the software-centric, embedded edge machine learning system-on-chip (MLSoC) company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220864540/en/ HTEC announces partnership extension with SiMa.ai, an embedded edge machine learning system-on-chip company. (Graphic: Business Wire) During a successful five-year collaboration, SiMa.ai and HTEC built an ML compiler, system drivers, and other complex AI-powered software tools to support SiMa.ai’s edge AI platform. SiMa.ai also leveraged HTEC’s AI- and ML-driven engineering and chip optimization expertise to enhance its purpose-built MLSoC™. Now, HTEC will support SiMa.ai’s strategic initiatives and help streamline the delivery of SiMa.ai solutions built on its cutting-edge ONE Platform for Edge AI, further enhancing the company’s hardware and software. “Collaborating w
ClickHouse Announces BYOC (Bring Your Own Cloud) on AWS20.2.2025 16:00:00 EET | Press release
As enterprises look to modernize and adopt cloud-native architectures, they must still comply with existing security mandates and geographic regulations. This becomes especially challenging with cloud-based database services, where any data leaving the enterprise Virtual Private Cloud (VPC) requires thorough security review. These considerations are critical for organizations in regulated industries or those handling sensitive customer data. ClickHouse BYOC was built to address this very challenge. It allows organizations to adopt unique capabilities of the fully-managed ClickHouse Cloud service, a leading real-time analytical database, while maintaining full ownership and control of their data within their VPC. In ClickHouse BYOC architecture, the data plane consisting of storage and compute resources resides in the customer VPC, which ensures that customers are able to adhere to data residency and governance requirements, while offloading operational complexities of managing ClickHou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom